Cite

    P Hilley et al.. “P028 Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease – what is the opportunity cost of improving access to health care?.” Journal of Crohn's and colitis, vol. 17, n.d., pp. i197–i198. http://access.bl.uk/ark:/81055/vdc_100179844252.0x000031